Abstract
In March 2019, the global COVID-19 pandemic caused by the novel SARS-CoV-2 coronavirus began. The first cases of SARS-CoV-2 infection occurred in November 19 in Wuhan, China. Preventive measures taken have not prevented the rapid spread of the virus to countries around the world. To date, there are approximately 3 million deaths, and a massive worldwide vaccination campaign has recently begun. SARS-CoV-2 uses the ACE-2 protein as an intracellular carrier. ACE-2 is a key component of the renin-angiotensin system (RAS), a key regulator of cardiovascular function. Considering the key role of ACE-2 in COVID-19 infection, both as an entry receptor and as a protective role, especially for the respiratory tract, and considering the variations of ACE-2 during the phases of viral infection, it is clear the important role that pharmacological regulation of RAS and ACE-2 may take. In this article, we describe the importance of ACE-2 in COVID-19 infection, the pharmacological aspects of a modulation with RAS-modifying agents, new therapeutic strategies, trying to provide a deep understanding and explanation of the complex mechanisms underlying the relationship between the virus and ACE-2, providing opinions and personal hypotheses on the best strategies of therapeutic intervention.
Keywords: ACE-2; COVID-19; RAS; SARS-CoV-2.
【저자키워드】 COVID-19, SARS-CoV-2, RAS, ACE-2, 【초록키워드】 SARS-CoV-2, viral infection, vaccination, SARS-COV-2 infection, COVID-19 pandemic, Variation, SARS-CoV-2 coronavirus, virus, renin-angiotensin system, ACE-2, Spread, Protein, Cardiovascular function, COVID-19 infection, Wuhan, Therapeutic strategies, variations, respiratory tract, preventive measures, angiotensin, deaths, preventive measure, Regulation, Renin, modulation, protective role, therapeutic intervention, entry receptor, explanation, complex mechanisms, pharmacological, country, Wuhan, China, occurred, caused, prevented, hypothese, complex mechanism, 【제목키워드】 angiotensin-converting enzyme 2, potential therapeutic target,